Table 3.
Treatment of acute and chronic HEV in HIV-infected patients.
| Phase | References | HEV genotype | Regimen | Outcome |
|---|---|---|---|---|
| Acute | Abravanel et al., 2017 | 3f | RBV 24 weeks | Treatment induced viral clearance |
| Acute | Robbins et al., 2014 | 3c | RBV 24 weeks 1,200 mg | Treatment induced viral clearance |
| Acute | Bouamra et al., 2013 | 3c | RBV 24 weeks 1,200 mg | Treatment induced viral clearance |
| Chronic | Dalton et al., 2011 | 3a | Peg-IFN 24 and 6 weeks of Peg-IFN/RBV | Treatment induced viral clearance |
| Chronic | Jagjit, Singh et al., 2013 | 3a | Peg-IFN 24 weeks | Treatment induced viral clearance |
| Chronic | Neukam et al., 2013 | 3 | RBV 24 weeks 1,200 mg | Viral relapse |
| Chronic | Neukam et al., 2013 | 3 | RBV 24 weeks 1,000 mg | Viral relapse |
| Chronic | Ingiliz et al., 2016 | 3 | RBV 20 weeks 800 mg | Treatment induced viral clearance |
| Chronic | Todesco et al., 2017 | 3i | 1° Peg-IFN/RBV 12 weeks 2° SOF/RBV 12 weeks |
1° Viral relapse 2° Viral relapse |
HEV, hepatitis E virus; RBV, ribavirin; Peg-IFN, pegylated interferon; SOF, sofosbuvir.